期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 466, 期 1-2, 页码 147-154出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/S0014-2999(03)01548-6
关键词
JTT-705; cholesteryl ester transfer protein (CETP) inhibitor; high density lipoprotein (HDL) cholesterol
This study evaluated JTT-705, S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate, as a cholesteryl ester transfer protein (CETP) inhibitor in several animal species. In vitro, JTT-705 inhibited plasma CETP activities of humans, rabbits, hamsters, cynomolgus monkeys and marmosets with IC50 values of 5.5, 1.0, 11.7, 2.4 and 6.3 muM, respectively. The thiol form (JTP-25203) also inhibited those activities with IC50 values of 2.8, 0.44, 0.52, 1.3 and 1.1 muM, respectively. Following oral administration to normolipidemic animals (rabbits, hamsters and marmosets), JTT-705 reduced plasma CETP activity, increased high density lipoprotein cholesterol (HDL-cholesterol), and decreased the ratio of non-HDL-cholesterol to HDL-cholesterol (atherogenic index) in all species. In marmosets, JTT-705 increased slow a-migrating lipoprotein (apolipoprotein E-rich HDL) in agarose gel electrophoresis, indicating that HDL metabolism in JTT-705-treated marmosets is similar to that in CETP-deficient humans. These results indicate that JTT-705 can be expected to inhibit plasma CETP activity and improve plasma lipoprotein profiles in a wide range of animal species, including humans. (C) 2003 Elsevier Science B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据